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Abstract
Ischemia-induced cerebral infarction is more severe in older animals as compared to younger animals, and is associated with
reduced availability of insulin-like growth factor (IGF)-1. This study determined the effect of post-stroke IGF-1 treatment, and
used microRNA profiling to identify mechanisms underlying IGF-1’s neuroprotective actions. Post-stroke ICV administration
of IGF-1 to middle-aged female rats reduced infarct volume by 39% when measured 24h later. MicroRNA analyses of
ischemic tissue collected at the early post-stroke phase (4h) indicated that 8 out of 168 disease-related miRNA were
significantly downregulated by IGF-1. KEGG pathway analysis implicated these miRNA in PI3K-Akt signaling, cell adhesion/
ECM receptor pathways and T-and B-cell signaling. Specific components of these pathways were subsequently analyzed in
vehicle and IGF-1 treated middle-aged females. Phospho-Akt was reduced by ischemia at 4h, but elevated by IGF-1
treatment at 24h. IGF-1 induced Akt activation was preceded by a reduction of blood brain barrier permeability at 4h post-
stroke and global suppression of cytokines including IL-6, IL-10 and TNF-a. A subset of these cytokines including IL-6 was
also suppressed by IGF-1 at 24h post-stroke. These data are the first to show that the temporal and mechanistic
components of post-stroke IGF-1 treatment in older animals, and that cellular components of the blood brain barrier may
serve as critical targets of IGF-1 in the aging brain.
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Introduction
Ischemic stroke is a leading cause of death worldwide and a
major cause of long-term disability in survivors. Stroke risk
increases with age [1] and occurs more frequently in older women
than men [2]. Poor recovery and long-term disability is greater in
postmenopausal women as compared to men [3,4] or young
women [5]. Experimental studies confirm worse stroke outcomes
in aged (16 months) female mice as compared to young (2–3
months) females [6], and this age-related severity is seen as early as
middle age (10–12 months) in female rats [7].
Middle age represents a critical window of stroke susceptibility
in females, specifically associated with declining ovarian function.
Acyclic, middle-aged female rats have constitutive increases in
blood brain barrier permeability [8] and reduced functional
capacity of critical support cells such as astrocytes [9], likely
contributing to their increased stroke severity. Paradoxically,
estrogen replacement to middle-aged or aged female rats is not
neuroprotective [7,10]. However, declining gonadal hormone
levels in aging females is also paralleled by reduction in other
endocrine factors such as IGF-1 [11]. Our previous work has
shown that circulating and parenchymal IGF-1 levels are lower in
middle-aged females compared to younger females rats [12].
IGF-1 is widely considered neuroprotective in brain injury and
stroke. Decreased IGF-1 levels are linked to increased risk [13]
and worse functional outcome after ischemic stroke [14]. In young
animals, exogenous IGF-1 reduces ischemic injury [15–17] and
promotes neuronal survival and angiogenesis [18,19]. IGF-1 is a
mitogen and activates the PI3k/Akt pathway that mediates cell
survival, however it’s role in ischemic middle-aged and aging
animals is poorly studied, as are the mechanisms underlying IGF-1
actions in this group.
A novel strategy was used to identify potential neuroprotective
mechanisms for IGF-1 in middle-aged rats, specifically, comparing
microRNA (miRNA) expression profiles in the ischemic brain.
MiRNA, a small non-coding RNA, are important regulators of
mRNA transcript stability [20] and gene translation [21]. MiRNA
have been used successfully as biomarkers for cancer, cardiovas-
cular and neurologic diseases [22] including stroke [23] as well as
therapeutic targets for these diseases in experimental models
[24,25]. In the present study, we report that a small cohort of
miRNAs were significantly downregulated by IGF-1 in ischemic
tissue from middle-aged females, and KEGG (Kyoto Encyclopedia
of Genes and Genomes) analysis of putative miRNA gene targets
implicated PI3K-Akt signaling pathways, as well as pathways
related to endothelial and immune cell function. Evaluation
specific components of these pathways showed that IGF-1’s
neuroprotective actions in middle-aged females was preceded by
improvement in the blood brain barrier and suppression of local
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inflammatory mediators, indicating a unique anti-inflammatory
role for IGF-1 in the aging brain and the blood brain barrier as a
novel target for IGF-1-mediated neuroprotection.
Materials and Methods
Middle-aged (9–11 mo. weight range 325–350 g) female
Sprague Dawley rats were purchased from Harlan Laboratories,
IN. All animals were housed in an AALAC-approved facility,
maintained on a constant photoperiod (12h light:dark cycles) and
fed ad libitum with laboratory chow (Harlan Telkad 8604) and
water. All animal procedures were performed in accordance with
National Institutes of Health guidelines for the humane care of
laboratory animals and approved by the Texas A&M University
(TAMU) Institutional Animal Care and Use Committee. All
surgical and terminal procedures were performed under anesthe-
sia.
Animals that were included in these studies met our previously
established criteria to be classified as reproductive senescent
[8,26,27], namely 5+ previous pregnancies and current persistent
diestrus. Persistent diestrus was determined by vaginal smears
obtained daily for 3 weeks. A total of 61 females met the criteria
for reproductive senescence and were included in the experiments.
All animals were fitted with intracerebroventricular (icv) cannulas
and were randomly assigned to receive either IGF-1 or saline. All
animals were also subject to middle cerebral artery occlusion
(MCAo) to mimic ischemic stroke. We observed 25% (16/61)
mortality due to stroke, which is typical for this middle-aged group
with the suture stroke model. Mortality was seen in both control
and IGF-1 treated animals. Animals were assigned to either 4h or
24h survival. Experimental groups for analysis of infarct, blood
brain barrier permeability and cytokine expression consisted of 6–
8 animals each in the control and IGF-1 treated groups.
Surgeries
Middle cerebral artery occlusion: Rats were anesthetized and
maintained at 37uC on heating pads. Animals were subjected to
middle cerebral artery occlusion (MCAo) via intraluminal suture.
Briefly, after the neck region was shaved and the skin disinfected
with ethanol, a ventral midline incision was made on the skin.
Superficial fascia on the right side of the neck was dissected and
the underlying muscles were blunt dissected to expose the right
common carotid (CCA), external (ECA) and internal carotid
arteries (ICA). The ECA was separated from the vagus nerve, and
tied off distally with silk sutures after cauterizing the small
branches. Microsurgical clamps were placed on CCA and ICA, a
loose tie was placed on the ECA and the free stump of ECA was
aligned with the ICA. A size 39 nylon 4.0 suture of 22 mm length
with a silicon-coated round tip (Doccol Corp., CA) was inserted
into ICA lumen through a small nick on the ECA between the two
ties. The suture was advanced along the ICA until it reached the
origin of the MCA (, 20 mm of suture) and secured in position
with nylon ties. The intraluminal suture was maintained for 90
min. and, then withdrawn. Tissue perfusion rate was monitored
using Laser-Doppler Flowmetry (Moor Instruments, UK) and the
perfusion index was calculated for both ischemic and reperfusion
time points. MCAo resulted in an 80% reduction of blood flow
compared to the pre-occlusion rate and re-perfusion restored the
perfusion index back to pre-occlusion levels.
Intracerebroventricular infusion of IGF-1
Animals were placed in a stereotaxic instrument (David Kopf
instruments, CA), a 28 gauge cannula was implanted into the right
lateral ventricle using the co-ordinates – 1.0 mm posterior to
bregma, –1.4 mm medial lateral, –3.5 mm from dural surface, as
described by [28], and anchored in place with loctite 454
(Braintree Scientific, MA). Animals were allowed to recover for
1 week following cannula implantation and prior to stroke surgery.
An Alzet osmotic minipumps (1003D, Alzet corp., CA, flow rate
1 ml/h) filled with human recombinant (hr) IGF-1 (R&D
laboratories, 100 mg/ml) primed overnight placed into a subcu-
taneous pocket between the scapula and spine, after 45 min of
ischemia. Previous studies have shown that IGF-1 is stable in Alzet
minipumps for upto 7 days and the dose of IGF-1 was found to be
effective [12,29]. Control animals were infused with artificial CSF.
All animals were terminated either 4h or 24h post-reperfusion.
Infarct Analysis
Infarct volume analysis was determined using our previous
procedures [12]. Briefly, the brain was removed from the cranium
immediately after decapitation and sliced into 2 mm coronal
sections using a brain matrix (Roboz, US). Brain slices were
incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC,
Sigma-Aldrich, MO) at 37uC. for 20 min and stained slices were
photographed using an Olympus digital camera attached to a
surgical microscope. Images were coded and infarct volume was
measured using image analysis software, Image J (NIH, MD) by an
experimenter who was blind to the codes. Total brain infarct was
calculated from 3–4 slices (per animal) and is expressed as the ratio
of infarct volume in the ischemic hemisphere to the total volume of
the non-ischemic hemisphere.
Molecular analyses:
RNA extraction: Brain tissue from the ischemic hemisphere of
IGF-1 and vehicle-treated controls was used for RNA extraction.
To each tube, containing 175 mg of brain tissue, 750 ml QIAzol
master mix (800 ml QIAzol and 1.25 ml 0.8 mg/ml MS2 (carrier)
RNA per sample) was added. Following a 5-minute incubation at
room temperature (RT), 200 ml chloroform was added to each
sample. After a 2-minute incubation at RT, samples were
centrifuged at 12,000xg for 15 minutes at 4uC. The aqueous
phase is then transferred to a fresh tube and mixed with ethanol
(1.5 vol). The sample was then loaded on to a RNeasy Mini Spin
Column and centrifuged for 30 seconds at RT, 13,000xg. After
sequential washes in RWT and RPE buffers, the columns were
transferred to a fresh tube and RNA eluted with 50 ml of DNase/
RNase-free water. Sample purity was assessed by Nanodrop
technology and a ratio of 1.8 was considered acceptable. Samples
were stored at –20uC until use.
PCR Amplification: Template RNA (samples) were incubated
with reverse transcriptase for 60 min at 42uC, followed by heat-
inactivation of the enzyme (5 min at 95uC) and used immediately.
cDNA was diluted 80-fold and then incubated with SYBRH Green
master mix. Ten ml was dispensed to each well of the 384-well
PCR plate. Plates were centrifuged at 192xg for 1min at 25uC
before insertion into the thermalcycler (ABI Thermal Cycler
7900HT). An activation/denaturation step (95uC, 10 min)
precedes 40 amplification cycles each at 95uC, 10 s, 60uC, 1
min, ramp-rate 1.6uC/s. Each microplate consists of 168 LNA-
microRNA primer sets of plasma/serum relevant human miRNA
and 7 reference microRNAs, for use with the ABI 7900HT
instrument. MicroRNA on this panel are found in tissue and fluids
and are culled from different diseases including various types of
cancer, neurological disorders/neurodegenerative diseases, aller-
gies/inflammation. Due to the multifactorial nature of stroke, this
panel was considered the most appropriate. All primers are LNA
modified which allows for uniform Tm, and confers greater
specificity, allowing for discrimination between miRNA sequences
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with single nucleotide differences. Normalization: Cycle Thresh-
olds (CT) were determined for each miRNA in each sample. CT
values for 5 reference miRNA in each sample were averaged and
then subtracted from each of the 168 miRNA of interest (DCT).
MicroRNA profiles were obtained from DCT values.
Protein extraction: Cortical and striatal tissue from the
ischemic and non-ischemic hemisphere was dissected and stored
frozen until use. Protein was extracted as described in [26,30].
Briefly, tissues were homogenized in lysis buffer (50 mM
TRis,pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM Na-orthova-
nadate,pH 10, 5 mM ZnCl2, 100 mM NaF, 10 mg/ml leupeptin,
10% glycerol, 5 mM ZnCl2, 10 mg/ml aprotinin, 1 mg/ml
leupeptin, 1 mM phenylmethylsulfonylfluoride in dimethylsulfox-
ide, and 1% Triton X-100) and centrifuged at 18000 rpm for 30
min. Supernatant was collected and stored at –20uC. until further
analysis. Protein concentrations were determined using BCA
protein assay kit (Pierce,IL).
Western blot analysis
Western blotting was performed as described previously [12,31].
Briefly, proteins (25 mg/lane) from the ischemic and non-ischemic
hemisphere were size-fractionated on SDS-Page gels, and trans-
ferred to nylon membranes (Life Technologies, CA). Membranes
were blocked and incubated with primary antibodies for either
phosphorylated Akt or ERK (1:200, SCBT, CA) followed by
incubation with HRP-conjugated secondary antibodies (1:2000,
Transduction laboratories, KY). Blots were visualized using the
Alpha Innotech imager in conjunction with the ECL detection
method. Thereafter, the blots were stripped and reprobed with the
pan-antibody for Akt and ERK. In each case, the intensity of ERK
and Akt positive bands were quantified using FluorChem software,
and phosphorylated protein signal was normalized to the
appropriate pan antibody signal.
For detection of heavy (H) and light (L) chain IgG, proteins
(25 mg/lane) from the ischemic and non-ischemic hemisphere
were size-fractionated on SDS-Page gels, and transferred to nylon
membranes (Life Technologies, CA) as before. Blots were
incubated with HRP-conjugated anti-rat IgG antibody
(1:1000,Vector Laboratories, CA) and processed as above to
visualize the immunoreactive signal. The IgG immunoreactive
signal was quantified and intensity of the band of the ischemic
hemisphere was normalized to the non-ischemic hemisphere.
Multiplex bead cytokine assay
Tissue expression for a panel of cytokine/chemokine was
measured in the ischemic and non-ischemic hemisphere of IGF-1
and vehicle treated animals, using a multiplexed magnetic bead
immunoassay (Milipore Corp. MA) following manufacturer’s
instructions. Briefly, the filter plate was blocked with assay buffer
for 10 min and decanted. Standards and samples was added into
appropriate wells, followed by addition of premixed beads and
incubated for 2h at room temperature on a plate shaker. Wells
were washed 2 times, 25 ml of detection antibody was added,
incubated for 1h incubation at room temperature (RT) and
followed by 30 min incubation with addition of 25 ml of
streptavidin-phycoerythrin per well. After 2 washes, beads were
resuspended in 150 ml of sheath fluid and a minimum of 50 beads
per analyte was analysed in a Bio-Plex suspension array system
(Bio-Rad Laboratories,CA). Cytokine/chemokine levels were
normalized to total protein content. The following chemokines
and cytokines were assessed: Granulocyte colony stimulating factor
(G-CSF), eotaxin, GM-CSF, interleukin (IL)-1a, leptin, macro-
phage inflammatory protein (MIP)-1a, MIP2, IL-4, IL1-b, IL-2,
IL-6, EGF, IL-13, IL-10, IL-12 phosphorylated 70 KDa (IL-12-p-
70), Interferon (IFN)-c, IL-5, IL-17A, IL-18, Chemokine C-motif
Ligand (CCL2), Interferon gamma induced protein (IP)-10,
Growth related oncogene/Keratinocyte derived chemokine
(GRO/KC), VEGF, Fractalkine, Lipoploysacharide-induced
CXC (LIX) chemokine, MIP-2, Tumor necrosis factor (TNF)- a,
RANTES (regulated on activation, normal T cell expressed and
secreted).
Thiobarbituric Acid Reactive Substances (TBARS) Assay
Lipid peroxidation in the brain tissue was determined using the
TBARS assay kit (Cayman chemical, MI) according to manufac-
turer’s instructions. Briefly, a mixture of 100 ml of sample,
standard and 100 ml of SDS was first prepared. To this mixture,
4 ml of color reagent was added and boiled for an hour. The
reaction was stopped on ice for 10 min and centrifuged for 10 min
at 1600 g. The supernatant (150 ml) was loaded on a 96 well plate
and absorbance was read at 540 nm in Tecan plate reader.
TBARS concentration was calculated from a malondialdehyde
Figure 1. Effect of IGF-1 on infarct volume: MCAo for 90 min
followed by reperfusion resulted in a cortical-striatal infarction as seen
in TTC-stained coronal sections. Quantitative analysis of infarct volume,
expressed as a ratio to the non-ischemic hemisphere, shows that post-
stroke IGF-1 treatment resulted in a 39% decrease in infarct size
compared to control after 24 h. Bars represent mean 6 SEM. N= 6–8 in
each group. *: p ,0.05.
doi:10.1371/journal.pone.0091427.g001
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(MDA) standard curve using Magellan software (CA) and
normalized to the amount of total protein.
Blood Brain Barrier Permeability Assay
Four hours following MCAo and reperfusion, animals were re-
anesthetized and injected with Evan’s blue (2% at a volume of
4 mL/kg body weight) via the right jugular vein [8]. After 40 min,
the animals were decapitated while under anesthesia. Brains were
removed from the cranium, meninges were carefully removed and
the brains were arranged in acrylic matrices (Braintree Scientific,
MA) for sectioning. Brain slices between +1.7 to –1.4 mm from
bregma [28] were collected. Cortical and striatal tissues were
dissected separately from both the ischemic and non-ischemic
hemispheres. Brain tissues were immediately weighed and dried in
an incubator at 55uC. Dry tissues were weighed, homogenized in
50% trichloroacetic acid, centrifuged at 10,000 rpm for 10 min,
Figure 2. MiRNA regulation by IGF-1 in the ischemic brain at 4h post stroke.MiRNAs that were significantly regulated (adjusted for FDR) are
graphically represented in a heat map format. Within the heat map, the vehicle-treated animals were used as ‘controls’ and are represented in black,
while IGF-1 treated animals are depicted in relation to vehicle controls (columns). All miRNA in this cohort were significantly downregulated by IGF-1
(shown in red) in comparison vehicle controls (rows). (B) Group differences in expression patterns of IGF-1 regulated miRNA are shown graphically,
with the ‘fold’ regulation indicated at the bottom right corner. Data (mean+SEM) are expressed are expressed as DCT, where an increased value
indicates decreased miRNA expression. N = 6/group p,0.05. (C) MiRNAs that were significantly regulated by IGF-1 treatment were subject to in silico
analysis (DIANA/miRPATH, see methods). Predicted gene targets for each miRNA were identified. The top 10 KEGG pathways represented by these
predicted targets are shown as a pie chart. Each slice represents the number of predicted target genes in the pathway, indicated within the slice. Each
pathway is color coded and labeled adjacent to the chart. The top 10 pathways were selected based on the smallest ‘‘p’’ value and the largest
number of target genes in the pathway.
doi:10.1371/journal.pone.0091427.g002
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and the supernatant was collected. Samples and standards
containing known concentrations of Evan’s dye were loaded on
a microplate and read at 620 nm (excitation); 680 nm (emission).
The concentration of Evan’s blue was determined from a linear
standard curve, using Magellan software (Tecan, Switzerland).
Data analysis
MiRNA profile analysis: MicroRNA expression data (DCT)
obtained from focus panels were uploaded into GenesifterH
Analysis Edition (GSEA, Geospiza/Perkin Elmer Seattle, WA)
software program. Differences in microRNA expression were
identified by t-tests, with Benjamini and Hochberg correction for
multiple comparisons at a cutoff a=0.05. MicroRNA that were
significantly regulated were graphically represented as a heat map.
Further in silico analysis was performed using DIANA-miRPath
v2.0 (Vlachos et al., 2012), with the microT-CDS algorithm.
Predicted and validated gene targets and the associated KEGG
pathways were identified using a modified Fischer’s exact test with
a FDR (Benjamini and Hochberg)-corrected p-value threshold of
, 0.05.
Statistical analysis for other assays: Effect of IGF-1 on infarct
volume and blood brain barrier permeability was analyzed by
Student’s t-test. Two-way ANOVA were used to determine the
effect of IGF-1 on inflammatory cytokines, TBARS, and
expression of Akt and ERK. Each ANOVA was coded for
treatment (IGF-1 or vehicle) as an independent variable and
hemisphere (ischemic or non-ischemic) as a repeated measure,
using the statistical package SPSS 21.0. Group differences were
considered significant at p,0.05. Results are expressed as mean 6
SEM.
Results
IGF-1 reduces infarct volume in the acute phase of ischemia-
reperfusion injury
To determine the effect of IGF-1 treatment on brain infarct
volume during the acute phase of stroke, female rats were
subjected to MCAo occlusion and exposed to ICV-delivered IGF-
1 or vehicle (artificial CSF, aCSF) treatment, immediately after
reperfusion. At 24h post MCAo, IGF-1-treated middle-aged
animals displayed a significant reduction (39%, p= 0.03) in infarct
volume as compared to vehicle-treated females (Figure 1),
indicating a significant neuroprotective effect for this peptide
hormone.
IGF-1 mediated neuroprotection: Mechanism of action
MiRNA regulation by IGF-1: To identify neuroprotective
mechanisms regulated by IGF-1, RNA from ischemic tissue from
vehicle and IGF-1 treated animals was obtained at an early acute
stroke phase (4h after MCAo), and interrogated using a focus
panel of disease-related miRNA. QPCR analysis of a panel of 168
miRNA revealed that 8 miRNAs were significantly regulated by
IGF-1 treatment after FDR (Figure 2A). These miRNA included
mir33a, 320b, 92b, 29b, 29c, 22, 30a, 15a. Within this subset,
Figure 3. Phospho-Akt and Akt expression in post-ischemic brain. pAkt and pan-Akt levels were analyzed by Western blot (top panels). pAkt
expression, normalized to pan-Akt, is shown in the histograms (lower panels). (A) p-Akt levels were reduced in both control and IGF-1-treated groups
in the ischemic hemisphere at 4h, as compared to the non-ischemic hemisphere (main effect of ischemia; p,0.05). (B) At 24h, p-Akt expression was
significantly increased in the ischemic hemisphere of the IGF-1-treated group as compared to the vehicle-treated group (interaction effect of
ischemia and IGF-1). Bars represent mean 6 SEM. n= 6 in each group. *: p ,0.05.
doi:10.1371/journal.pone.0091427.g003
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IGF-1 decreased expression of all miRNA (Figure 2B), ranging
from a 1.8–4.82 fold downregulation.
In silico analysis tools (DIANA-miRPath v2.0, and target
database microT-CDS) was utilized to obtain predicted gene
targets and associated Kyoto Encyclopedia of Genes and Genomes
(KEGG) pathways of the IGF-1 regulated miRNAs. In total, 76
KEGG pathways were identified and from these, the 10 most
relevant KEGG pathways are shown in Figure 2C. The top 10
pathways were selected based on the following criteria: smallest ‘p’
values for the union of common pathways targeted by all miRNAs,
and the largest number of genes represented in those pathways,
both indicators of robust pathways. This included the PI3-Akt
signaling pathway, which is closely associated with cell survival
and protection, and is also a principal component of the
neurotrophin and insulin signaling pathways. A second large
group of pathways identified by miRNA/KEGG analysis center
around maintenance of cell structure, such as focal adhesion, actin
cytoskeleton and ECM-receptor interactions, indicative of endo-
thelial function. Finally, a third set of pathways regulate T and B
cell signaling, cell types that are recruited to the brain following
stroke. In subsequent studies, specific components or markers of
these pathways were assessed in IGF-1 and vehicle-treated
animals.
IGF-1 effect on survival kinases: To test the Akt pathway, Western
blot analysis was used to determine the effect of IGF-1 on the
expression of phosphorylated-Akt and the related MAP kinase,
ERK in brain lysates. At 4h post-stroke (Figure 3A), pAkt
expression was reduced in the ischemic hemisphere (main effect
of hemisphere, (F(1,10) = 14.91;p = 0.003) in vehicle and IGF-1
treated animals. However, at 24h post stroke (Figure 3B) IGF-1
treatment significantly enhanced pAkt expression in the ischemic
hemisphere (interaction effect, hemisphere x treatment;
F(1,10) = 22.49;p = 0.001).
Ischemia upregulated activated ERK-1 and ERK-2 at 4h (main
effect of hemisphere, (F(1.10) = 23.20;p = 0.001 &
F(1.10) = 10.74;p = 0.008 respectively; Figure 4A) while at 24 h,
both ERK-1 and ERK-2 were elevated in the ischemic
hemisphere (main effect of hemisphere, (F(1.10) = 18.39;p = 0.002
& F(1,10) = 41.62;p = 0.00007 respectively; Figure 4B). IGF-1,
however, did not alter ERK phosphorylation in either hemisphere
at the 4h and 24h time points (Figure 4A& B).
Effect of IGF-1 on Oxidative stress: Post-stroke cell death is
characterized by rapid necrotic cell death with elevated levels of
reactive oxygen species. We assessed whether IGF-1 altered the
levels of thiobarbituric reactive species (TBARS), as a proxy
measure of reactive oxygen species. As shown in Figure 5A, at 4h
TBARS values were significantly higher in the ischemic hemi-
sphere, indicative of ischemia-induced cell death seen in this
hemisphere. However, IGF-1 did not attenuate TBAR levels in
ischemic tissue. At 24h post-stroke (Figure 5B), there was no
difference between the two hemispheres, indicating an abatement
of reactive oxidative substances at this later time point. IGF-1 had
no effect on TBARS at this time point as well.
IGF-1 effect on blood brain barrier permeability: Blood brain barrier
permeability was assessed by Evan’s blue extravasation and by IgG
expression in brain tissue. For this study, the cortex and striatum
were dissected and analyzed separately. A 2-way ANOVA
indicated that the amount of dye extravasation was greater in
the striatum as compared to the cortex (F(1,14): 15.04; p = 0.002).
However, IGF-1 treatment improved post-stroke barrier integrity
Figure 4. Phospho-ERK and pan ERK expression in post-ischemic brain. pERK and pan ERK were analyzed by Western blot (top panels). pERK
expression, normalized to ERK, are shown in the histograms (lower panels). (A) p-ERK1 level increased in the ischemic hemisphere at 4h, as compared
to the non-ischemic hemisphere (main effect of hemisphere, p,0.05). (B) At 24h, both p-ERK1 & 2 were significantly increased in the ischemic
hemisphere (main effect of hemisphere; p,0.05). IGF-1 did not affect pERK expression at either time point. Bars represent mean6 SEM. n = 6 in each
group. *: p ,0.05.
doi:10.1371/journal.pone.0091427.g004
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in both regions (F(1,14):5.97; p = 0.028), reducing dye accumulation
by 62% in the cortex and 57% in the striatum (Figure 6A).
IgG expression was used as an additional surrogate marker for
post-stroke changes in blood brain barrier function. Western blot
analysis from ischemic brain lysates showed the presence of both
heavy and light chain IgG at 4 & 24h time points (p = 0.001 and
0.003 respectively; Figure 6B & C). The expression of IgG-H in
the ischemic hemisphere, normalized to the non-ischemic
hemisphere, was significantly greater in the vehicle-treated group
as compared to the IGF-1-treated group at both time points,
supporting the conclusion that peptide treatment reduced blood
brain barrier permeability.
Effect on IGF-1 on cytokine and chemokine expression: Ischemia triggers
inflammation, which plays a major role in exacerbating stroke
injury. A panel of cytokines and chemokines were examined in
ischemic brain lysates obtained from animals terminated 4h and
24h post-stroke. At 4h post-stroke, virtually all cytokines were
elevated in the ischemic hemisphere (Figure 7A; indicated by
arrows). IGF-1 treatment caused a significant suppression of
several pro- and anti-inflammatory cytokines (Figure 7A; indicated
by downward arrows), ranging from a 2 to 5-fold suppression. In
most cases, IGF-1 suppressed cytokines only in the ischemic
hemisphere (interaction effect hemisphere x treatment). These
included IL-6, TNF-a, IFN-g, IL1- b, GM-CSF, eotaxin, leptin,
IL-5 and IL-10. In the case of IL-13, LIX and IL-17a, IGF-1
suppressed these cytokines in both hemispheres (main effect of
treatment for each; Figure 7A, last column).
Cytokine expression was also examined at 24h post-stroke
(Figure 7B) At this time point, IGF-1 treatment suppressed CCL2,
IL-6 and GRO-KC in the ischemic hemisphere (interaction effect
hemisphere x treatment) and IL-13 in both hemispheres (main
effect of treatment). Both IL-6 and IL-3 were suppressed by IGF-1
at 4h as well, indicating a sustained action on specific inflamma-
tory mediators.
Discussion
These studies show that post-stroke IGF-1 treatment reduces
infarct volume in middle-aged female rats. Using miRNA and
putative target genes as a strategic tool, we show novel effects of
IGF-1-mediated neuroprotection in an aging model. While IGF-
1’s effects on Akt signaling are well known, this study demonstrates
for the first time that IGF-1’s neuroprotective effects are preceded
by an attenuation of stroke-induced blood brain barrier damage,
concomitant with a rapid immunosuppressive effect in brain, and
a sustained anti-inflammatory action.
Although miRNA have been used successfully as biomarkers
[22,23] as well as therapeutic targets [24,25] for disease such as
Figure 5. Expression of TBARS: (A) TBARS levels were increased with ischemia-reperfusion at 4h in both control and IGF-1 group compared to
non-ischemic hemisphere. IGF-1 had no effect on TBARS levels. (B) At 24h post stroke, TBARS were similar in the ischemic and non-ischemic
hemisphere and were not altered by IGF-1 treatment. Bars represent mean 6 SEM. n = 6–8 in each group. *: p,0.05.
doi:10.1371/journal.pone.0091427.g005
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stroke, the present study employed a discovery-based model to
identify potentially novel neuroprotective pathways for stroke. We
identified 8 miRNA that were significantly downregulated by IGF-
1 treatment, and used these miRNA to develop gene ontology
patterns. Although gene ontologies suggest putative targets, and
are incompletely validated, identification of the PI3K-Akt pathway
through the miRNA/KEGG analysis underscores the promise of
this approach. Akt signaling is a central component of neurotro-
phin and insulin signaling pathways and is known to promote cell
survival, proliferation and differentiation [32]. The present data
and published reports [16,33] show that pAkt is attenuated
following cerebral ischemia. Furthermore, IGF-1 has been shown
to stimulate cell survival pathways [34,35] in vitro and in disease
models such as subarachnoid hemorrhage [36], neonatal hypoxia
ischemia [37] hippocampal trimethytin toxicity [38] and Parkin-
son’s disease [29]. While IGF-1 mediated Akt activation has been
shown in a neonatal model of hypoxia-ischemia [37], the present
study is the first to show that IGF-1 elevates pAkt in an aging
stroke model.
The miRNA-based pathways also indicated that structural
elements of the cerebral microvasculature, such as focal adhesion,
ECM-receptor interactions and actin cytoskeleton regulation, may
be implicated in IGF-1 mediated neuroprotection. Several genes
within these pathways include the integrins, and integrin-
dependent downstream signaling proteins such Fyn, Rho-associ-
ated protein kinase (ROCK) and Rac1 [39]. Integrins constitute
one the best-characterized ECM adhesion receptors of the brain
microvasculature, including the blood brain barrier [40]. The
blood brain barrier is often affected in stroke patients [41,42] and
in experimental stroke models in young [43,44] and aging rodents
[6,45,46]. Improvements in barrier function are shown to improve
stroke outcome [47,48]. Ischemia-reperfusion induces structural
and molecular changes in the brain vasculature and adjacent cells,
causing dysregulation of the barrier and promoting neural
inflammation. Striatal infarction and stroke-mediated blood brain
barrier dyregulation is much greater compared to the cortex,
possibly due to the geometry of striatal arteries and inadequate
collateral circulation to this region. IGF-1, however, significantly
reduced blood brain barrier permeability in both the cortex and
striatum, as shown by dye extravasation and IgG expression. The
latter are the most frequently used assays for blood brain barrier
permeability, however, newer analyses such as the use of size-
graded dextrans would more precisely determine the extent of
barrier permeability.
IGF-1 may protect the blood brain barrier of older animals by
directly enhancing survival of endothelial cells, although such
actions may be limited during the early phase of stroke. In the
present study, IGF-1 did not promote Akt activation at the 4h time
point. In fact, several studies have indicated that rapid cell death,
which occurs in the early aftermath of ischemia, may hinder IGF-1
action. Reactive oxygen species, that accumulate in the early
phase of ischemic injury, reduce pAkt [49] and impair IGF-1-
mediated signaling. The elevated TBARS seen in the present study
at 4h post-stroke is consistent with this hypothesis. Elevated levels
of glutamate, typically seen following ischemic injury, have also
been shown to reduce Akt activation in vitro with a loss of sensitivity
to IGF-1 by alternate phosphorylation of the IGFR docking site
[50]. Thus, IGF-1 may promote barrier integrity by alternate
methods such as maintaining paracellular junctions. IGF-1 has
been shown to increase transepithelial electrical resistance (a
measure of barrier function) by regulating occludin and claudin-3
in submandibular gland cells [51], zona occludens (ZO)-1 in A431
Figure 6. Effect of IGF-1 on ischemia-reperfusion induced blood brain barrier permeability. (A). Evans blue dye extravasation: IGF-1
treatment significantly reduced ischemia-induced increase in blood brain barrier permeability at 4h as indicated by decreased Evan’s blue dye in both
cortex and striatum. Concentration of Evan’s blue is expressed as ratio of dye accumulation in the ischemic hemisphere to the non-ischemic
hemisphere. Bars represent mean 6 SEM. n = 6–8 in each group. *: p ,0.05. (B) IgG expression: Western blot analysis of light and heavy chain IgG
expression indicated that IGF-1 treatment reduced IgG-heavy chain expression at both 4h and 24h post stroke.
doi:10.1371/journal.pone.0091427.g006
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human epidermoid carcinoma cells [52] and claudin-1 in
osteoblast cells [53]. IGF-1 receptors have been identified on
human microvascular endothelial cells [54] and aortic endothelial
cells [55] although IGF-1’s effects on the molecular properties of
the blood brain barrier are poorly understood. Specifically,
analysis of brain microvessels and expression of junction proteins
following IGF-1 treatment are urgently needed.
Dysregulation of the blood brain barrier coupled with the local
inflammatory response triggers infiltration of circulating neutro-
phils, macrophages and T-cells [56,57] which plays a cardinal role
in the pathogenesis of cerebral ischemia particularly during the
Figure 7. IGF-1 mediated regulation of inflammatory cytokines in post-ischemic brain. (A). Multiplex analysis of brain tissue lysates from
the ischemic and non-ischemic hemisphere at 4h post stroke. The summary table shows each cytokine,and its regulation by ischemia or by IGF-1.
Almost all cytokines were upregulated by ischemia. IGF-1 decreased the expression of approximately half of the cytokines on this panel (column 3;
indicated by downward arrows and fold change), in the ischemic hemisphere and a few in both hemispheres (last column). (B) At 24 h, IL-6 and IL-13
continued to be suppressed in the IGF-1-treated group, as well as the chemokines GRO-KC and CCL2. n = 6-8 in each group; p,0.05 in each case.
doi:10.1371/journal.pone.0091427.g007
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acute stage of stroke onset [58,59]. Increased infarct volume in
aged females, for example, is associated with greater T-cell
infiltration as compared to young females and age-matched males
[60]. Consistent with previous stroke studies [61,62], we also
observed an increase in several brain inflammatory cytokines
including IL-6, TNF-a, IL-1b in the ischemic hemisphere of
vehicle treated animals. IGF-1 treatment, however, exerted a
profound suppressive action on the stroke-induced immune
response as early as 4h, decreasing the expression of both pro
and anti-inflammatory cytokines. At 24 hours post-stroke, IGF-1
treatment continued to inhibit selective pro-inflammatory mark-
ers, such as IL-6, the pleitrophic cytokine IL-13 and the
chemoattractants CCL2 and GRO-KC. These findings argue
that IGF-1 exhibits a biphasic action, an immediate, antigen non-
specific or global immunosuppression followed by inhibition of
specific pro-inflammatory cytokines at a later time point,
culminating in reduced ischemic injury.
While the early global suppression of cytokine/chemokine
expression by IGF-1 may be secondary to its effect on barrier
integrity, the continued suppression of specific cytokines at the 24
hour time point suggests that IGF-may also exert a direct anti-
inflammatory effect. KEGG pathway analysis indicated that IGF-
1 regulated miRNA also impact T and B cell signaling, where key
target genes include PDCD1, which negatively regulates the
immune responses through the T-cell receptor (TCR) [63], and
LYN, which encodes the tyrosine protein kinase LYN, an inhibitor
of myeloid lineage proliferation [64], suggesting that IGF-1
regulation of miRNA may suppress immune cell proliferation
and differentiation. However, little is known of IGF-1’s direct
actions on cytokine expression in leukocytes, and in some cases, its
actions appear to be contradictory. For example, in mast cells,
IGF-1, acting via PI3-K, stimulates IL-6 and TNF-a while
attenuating IL-1b [65] while in muscle cells, IGF-1 treatment
reduces IL-6 and TNF-a via suppression of TLR4 [66]. An
important future direction for this work is the direct assessment
IGF-1 actions on T and B cell cohorts recruited to the ischemic
brain.
The animal model used in these studies was intended to mimic
an important demographic that is at a higher risk for stroke as well
as stroke severity, namely middle-aged females, where ovarian
hormones such as estrogen are reduced as well as other endocrine
mediators such as IGF-1, thyroid hormone and Vitamin D. In
middle-aged female rats, we have shown that estrogen treatment is
not neuroprotective [7,12], however estrogen treatment coupled
with IGF-1 overcomes the neurotoxic effects of estrogen in this
population [12]. The role of IGF-1 treatment alone on this
estrogen-deficient population has not been explored previously.
Collectively, these data suggest that post-stroke IGF-1 treatment
improves stroke outcome by minimizing the impact of stroke on
blood brain barrier disruption and by shaping the post-stroke
neuroinflammatory profile.
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